Brexanolone is under clinical development by Sage Therapeutics and currently in Phase I for Alcohol Dependence.
Gilead’s M&A appetite is for deals in the ‘mid-single-digit billions,’ CEO says
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS